For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...